Clinical Trials Logo

Doses clinical trials

View clinical trials related to Doses.

Filter by:
  • None
  • Page 1

NCT ID: NCT04356482 Recruiting - COVID-19 Clinical Trials

CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19

COPLASCOV19
Start date: May 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients. Once the dose will be determined by each type of patient group (severely ill vs. very severely ill) has been determined, phase 2 of the study will begin, where the safety and efficacy of the use of plasma will be evaluated based on clinical, imaging and laboratory criteria. So, our hypotheses are: 1. Is there a minimum effective dose to treat seriously ill patients with convalescent plasma with COVID-19? 2. the plasma dose with the minimum effective effect will improve the clinical, laboratory and clearance conditions of the presence of the virus in the severely ill patient?